Success Metrics

Active Trials
4(67%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
5
83%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Recruiting4
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

not_yet_recruiting233%
recruiting467%

Recent Activity

4 active trials
Showing 5 of 6
not_yet_recruitingphase_2

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

NCT07623642
recruitingphase_1

GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study

NCT07457281
not_yet_recruitingphase_1

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

NCT07307053
recruitingphase_1

Study of GV20-0251 in Participants With Solid Tumor Malignancies

NCT07070518
recruitingphase_1

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

NCT07106827
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07623642Phase 2

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Not Yet Recruiting
NCT07457281Phase 1

GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study

Recruiting
NCT07307053Phase 1

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Not Yet Recruiting
NCT07070518Phase 1

Study of GV20-0251 in Participants With Solid Tumor Malignancies

Recruiting
NCT07106827Phase 1

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

Recruiting
NCT05669430Phase 1

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6